Diagnostics and therapeutics for osteoporosis

Abstract

Diagnostics and therapeutics for osteoporosis, which are bases upon the identification of a subjects IL-1 haplotype and genotype pattern are described.

1 . A method for detecting whether a subject is predisposed to developing osteoporosis or complication thereof, comprising detecting allele 2 of the −511 marker of IL-1B, wherein the presence of allele 2 of the −511 marker of IL-1B indicates that the subject is predisposed to the development of osteoporosis or complication thereof. 
     
     
         2 . The method of  claim 1  wherein the complication is vertebral fracture and wherein the presence of allele 2 of the −511 marker of IL-1B indicates that the subject is predisposed to the development of vertebral fracture. 
     
     
         3 . The method of  claim 1  wherein the complication is low bone mineral density (BMD) and wherein the presence of allele 2 of the −511 marker of IL-1B indicates that the subject is predisposed to the development of low BMD. 
     
     
         4 . A method for detecting whether a subject is predisposed to developing osteoporosis or complication thereof, comprising detecting allele 2 of the +2018 marker of IL-1RN, wherein the presence of allele 2 of the +2018 marker of IL-1RN indicates that the subject is predisposed to the development of osteoporosis or complication thereof. 
     
     
         5 . The method of  claim 4  wherein the complication is vertebral fracture and wherein the presence of allele 2 of the +2018 marker of IL-1RN indicates that the subject is predisposed to the development of vertebral fracture. 
     
     
         6 . The method of  claim 4  wherein the complication is low bone mineral density (BMD) and wherein the presence of allele 2 of the +2018 marker of IL-1RN indicates that the subject is predisposed to the development of low BMD. 
     
     
         7 . A method for detecting whether a subject is predisposed to developing osteoporosis or complication thereof, comprising detecting allele 2 of the −511 marker of IL-1B and allele 2 of the +2018 marker of IL-1RN, wherein the presence of both alleles indicates that the subject is predisposed to the development of osteoporosis or complication thereof. 
     
     
         8 . The method of  claim 7  wherein the complication is vertebral fracture and wherein the presence of allele 2 of the −511 marker of IL-1B and allele 2 of the +2018 marker of IL-1RN indicates that the subject is predisposed to the development of vertebral fracture. 
     
     
         9 . The method of  claim 7  wherein the complication is low bone mineral density (BMD) and wherein the presence of allele 2 of the −511 marker of IL-1B and allele 2 of the +2018 marker of IL-1RN indicates that the subject is predisposed to the development of low BMD. 
     
     
         10 . A method for detecting whether a subject is predisposed to developing osteoporosis or complication thereof, comprising detecting allele 2 of +4845 marker of IL-1A, wherein the presence of allele 2 of +4845 marker of IL-1A indicates that the subject is predisposed to the development of osteoporosis or complication thereof. 
     
     
         11 . The method of  claim 10  wherein the complication is vertebral fracture and wherein the presence of allele 2 of +4845 marker of IL-1A indicates that the subject is predisposed to the development of vertebral fracture. 
     
     
         12 . The method of  claim 10  wherein the complication is low bone mineral density (BMD) and wherein the presence of allele 2 of +4845 marker of IL-1A indicates that the subject is predisposed to the development of low BMD. 
     
     
         13 . A method for detecting whether a subject is predisposed to developing osteoporosis or complication thereof, comprising detecting allele 2 of −3737 marker of IL-1B, wherein the presence of allele 2 of −3737 marker of IL-1B indicates that the subject is predisposed to the development of osteoporosis or complication thereof. 
     
     
         14 . The method of  claim 13  wherein the complication is vertebral fracture and wherein the presence of allele 2 of −3737 marker of IL-1B indicates that the subject is predisposed to the development of vertebral fracture. 
     
     
         15 . The method of  claim 13  wherein the complication is low bone mineral density (BMD) and wherein the presence of allele 2 of −3737 marker of IL-1B indicates that the subject is predisposed to the development of low BMD. 
     
     
         16 . A method for detecting whether a subject has a reduced risk for developing osteoporosis or complication thereof, comprising detecting allele 2 of +3954 marker of IL-1B, wherein the presence of allele 2 of +3954 marker of IL-1B indicates that the subject has a reduced risk for developing of osteoporosis or complication thereof. 
     
     
         17 . The method of  claim 16  wherein the complication is vertebral fracture and wherein the presence of allele 2 of +3954 marker of IL-1B indicates that the subject has a reduced risk for the development of vertebral fracture. 
     
     
         18 . The method of  claim 16  wherein the complication is low bone mineral density (BMD) and wherein the presence of allele 2 of +3954 marker of IL-1B indicates that the subject has a reduced risk for the development of low BMD.